Drug profile · INN
avatrombopag maleate
DOPTELET
avatrombopag maleate (DOPTELET) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — avatrombopag maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
avatrombopag maleate (DOPTELET) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombopoietin receptor agonist
Primary target: Thrombopoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is avatrombopag maleate?
avatrombopag maleate (DOPTELET) is a thrombopoietin receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for avatrombopag maleate?
DOPTELET is a marketed brand name for avatrombopag maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of avatrombopag maleate?
avatrombopag maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.